No Data
Institutional Investors May Adopt Severe Steps After Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Latest 14% Drop Adds to a Year Losses
Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 26% But Its Business Is Yet to Catch Up
We're Keeping An Eye On Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Rate
Daily Investors : Hey I started a Bio Tech group, I know your on the same exact thing. If you want in you can. It is only for Bio and Major Pharm. But just what iv put in their over the weekend and today. Def worth it, if you want in send me a FR and I'll add you in
Daily Investors : * Editas Medicine laid off 65% of its workforce after failing to find a partner for its reni-cel program.
* Medtronic's latest PillCam completed its first patient procedure.
* AbbVie acquired oral peptide biotech Nimble for $200 million.
* Novartis paid PTC $1 billi...
Trytosaveabit OP Daily Investors : Thank you! I’ll have to think it over. I’m so busy already that I’m not sure if I’ll be able to contribute much! But again thank you